John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Vanguard US Value Factor ETF
VFVA
$942M
| $227K | ﹤0.01% |
1,900
-1,400
| -42% | -$157K |
|
2627
Rigel Pharmaceuticals
RIGL
$873M
| $226K | ﹤0.01% |
15,303
+4,986
| +48% | +$67.2K |
|
|
THRD
2628
DELISTED
Third Harmonic Bio
THRD
| $225K | ﹤0.01% |
+23,848
| New | +$232K |
|
2629
Quad
QUAD
$526M
| $225K | ﹤0.01% |
+42,342
| New | +$229K |
|
2630
Kayne Anderson Energy Infrastructure Fund
KYN
$2.46B
| $224K | ﹤0.01% |
+22,333
| New | +$202K |
|
2631
Traeger
COOK
$160M
| $224K | ﹤0.01% |
1,767
-1,268
| -42% | -$144K |
|
2632
Heron Therapeutics
HRTX
$61.3M
| $223K | ﹤0.01% |
+80,564
| New | +$203K |
|
2633
Five Star Bancorp
FSBC
$1.1B
| $223K | ﹤0.01% |
9,891
-5,900
| -37% | -$141K |
|
2634
Crexendo
CXDO
$210M
| $222K | ﹤0.01% |
+46,176
| New | +$256K |
|
|
MLNK
2635
DELISTED
MeridianLink
MLNK
| $222K | ﹤0.01% |
11,874
-6,000
| -34% | -$122K |
|
2636
Oil-Dri
ODC
$1.33B
| $222K | ﹤0.01% |
5,948
-8,722
| -59% | -$301K |
|
2637
PUT
DaVita
DVA
$11.3B
| $221K | ﹤0.01% |
+1,600
| New | +$192K |
|
2638
Republic Bancorp
RBCAA
$1.85B
| $221K | ﹤0.01% |
4,326
-1,093
| -20% | -$55K |
|
|
NCZ
2639
Virtus Convertible & Income Fund II
NCZ
$296M
| $221K | ﹤0.01% |
+18,445
| New | +$214K |
|
2640
KT
KT
$9.16B
| $220K | ﹤0.01% |
+15,668
| New | +$216K |
|
2641
Sprouts Farmers Market
SFM
$8.01B
| $220K | ﹤0.01% |
3,405
-54,797
| -94% | -$3.05M |
|
2642
PUT
Valvoline
VVV
$4.2B
| $218K | ﹤0.01% |
+4,900
| New | +$195K |
|
2643
The Bancorp
TBBK
$2.73B
| $218K | ﹤0.01% |
6,523
-13,506
| -67% | -$538K |
|
2644
National Healthcare
NHC
$3.52B
| $217K | ﹤0.01% |
2,300
| – | – |
|
|
OKUR
2645
OnKure Therapeutics
OKUR
$156M
| $217K | ﹤0.01% |
13,059
-5,188
| -28% | -$85.6K |
|
2646
FTAI Infrastructure
FIP
$446M
| $217K | ﹤0.01% |
34,495
-159,475
| -82% | -$740K |
|
2647
Corporacion America
CAAP
$4.05B
| $215K | ﹤0.01% |
+12,799
| New | +$198K |
|
2648
Interparfums
IPAR
$3.73B
| $214K | ﹤0.01% |
+1,524
| New | +$216K |
|
2649
Fulton Financial
FULT
$4.52B
| $214K | ﹤0.01% |
+13,449
| New | +$210K |
|
2650
Rush Enterprises Class A
RUSHA
$8.36B
| $213K | ﹤0.01% |
3,985
-30,300
| -88% | -$1.43M |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.